NCT07329933 Dexamethasone, Dexmedetomidine and Their Combination on Post op. GIT Function Measured by I-FFED Score Post Laparoscopic Cholecystectomy
| NCT ID | NCT07329933 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Benha University |
| Condition | GIT Function |
| Study Type | INTERVENTIONAL |
| Enrollment | 160 participants |
| Start Date | 2025-12-15 |
| Primary Completion | 2026-05-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 160 participants in total. It began in 2025-12-15 with a primary completion date of 2026-05-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to learn the effect of Dexamethasone and Dexmedetomidine and Their Combination on Post op. GIT Function Measured by I-FFED Score Post Laparoscopic Cholecystectomy What medical problems do participants have when taking Dexamethasone and Dexmedetomidine? Researchers will compare Dexamethasone and Dexmedetomidine and Their Combination to a placebo (a look-alike substance that contains no drug) to see the effect on Post op. GIT Function Measured by I-FFED Score Post Laparoscopic Cholecystectomy Participants will receive Dexamethasone 8 mg IV + Saline IV (total volume 10 ml) over 10 minutes administered after induction of anesthesia. Participants will receive Dexmedetomidine 0.5 mcg /kg IV + Saline IV (total volume 10 ml) over 10 minutes administered after induction of anesthesia. Participants will receive Dexamethasone 8 mg IV + Dexmedetomidine 0.5 mcg/kg IV+ Saline IV (total volume 10 ml) over 10 minutes administered after induction of anesthesia. Participants will receive Saline IV (total volume 10 ml) over 10 minutes administered after induction of anesthesia
Eligibility Criteria
Inclusion Criteria: * . Age 18-65 years. * American Society of Anesthesiologists (ASA) physical status I or II. * Scheduled for elective laparoscopic cholecystectomy surgery under general anesthesia. * Ability to provide written informed consent Exclusion Criteria: * Known allergy or contraindication to any study drug (dexamethasone, dexmedetomidine, or placebo). * Pre-existing gastrointestinal motility disorders (e.g., gastroparesis, inflammatory bowel disease). * Chronic use of opioids, steroids, or antiemetics. * History of severe cardiac disease (e.g., high-grade AV block, severe bradycardia). * Uncontrolled diabetes mellitus (HbA1c \> 8.0%). * Emergency surgery or conversion to open surgery. * Pregnancy or breastfeeding. * Morbid obesity (BMI \>40). * Severe hepatic or renal dysfunction.
Frequently Asked Questions
Who can join the NCT07329933 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying GIT Function. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07329933 currently recruiting?
Yes, NCT07329933 is actively recruiting participants. Visit ClinicalTrials.gov or contact Benha University to inquire about joining.
Where is the NCT07329933 trial being conducted?
This trial is being conducted at Banhā, Egypt.
Who is sponsoring the NCT07329933 clinical trial?
NCT07329933 is sponsored by Benha University. The trial plans to enroll 160 participants.